Serum alkaline phosphatase during hormone treatment in early postmenopausal women. A model for establishing optimal prophylaxis and treatment in postmenopausal osteoporosis
- PMID: 6385631
- DOI: 10.1111/j.0954-6820.1984.tb03764.x
Serum alkaline phosphatase during hormone treatment in early postmenopausal women. A model for establishing optimal prophylaxis and treatment in postmenopausal osteoporosis
Abstract
We propose a new model for use in establishing optimal treatment of postmenopausal osteoporosis. When hydroxyproline is taken as an estimate of bone resorption and alkaline phosphatase (ALP) of bone formation, the model indicates that the difference between hydroxyproline and ALP is reflected in the negative calcium balance, and thus the decline in bone mineral content (BMC). Since BMC increases during oestrogen treatment in postmenopausal women, in whom ALP declines gradually, it is postulated that this only happens because of a rapid decline in hydroxyproline. This decline together with BMC, must be dose-related since changes in ALP are uncorrelated to the oestrogen dose. This model fits the generally accepted opinion that the effect of oestrogen on bone loss in postmenopausal osteoporosis is limited, declines with age, and is dose-related. The model indicates that oestrogen treatment should be introduced early after the menopause in order to obtain the optimum prophylactic effect.
Similar articles
-
Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis.Lancet. 1985 Oct 12;2(8459):800-1. doi: 10.1016/s0140-6736(85)90794-9. Lancet. 1985. PMID: 2864532 Clinical Trial.
-
Serum bone Gla protein variations during estrogen and calcium prophylaxis of postmenopausal women.Calcif Tissue Int. 1984 Sep;36(5):536-40. doi: 10.1007/BF02405361. Calcif Tissue Int. 1984. PMID: 6441624 Clinical Trial.
-
Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women.Maturitas. 1988 May;10(1):51-8. doi: 10.1016/0378-5122(88)90131-4. Maturitas. 1988. PMID: 3041248 Clinical Trial.
-
Postmenopausal osteoporosis--intervention and prophylaxis. A review.J Chronic Dis. 1987;40(8):743-60. doi: 10.1016/0021-9681(87)90126-3. J Chronic Dis. 1987. PMID: 3298299 Review.
-
Osteoporosis and osteomalacia.Clin Endocrinol Metab. 1980 Mar;9(1):177-205. doi: 10.1016/s0300-595x(80)80026-0. Clin Endocrinol Metab. 1980. PMID: 6998609 Review. No abstract available.
Cited by
-
Sub-chronic exposure to low concentration of dibutyl phthalate affects anthropometric parameters and markers of obesity in rats.Environ Sci Pollut Res Int. 2017 Nov;24(32):25462-25467. doi: 10.1007/s11356-017-9952-y. Epub 2017 Aug 19. Environ Sci Pollut Res Int. 2017. PMID: 28823096
-
Assessment of osteoporotic alterations in achondroplastic patients: a case series.Clin Rheumatol. 2013 Mar;32(3):399-402. doi: 10.1007/s10067-012-2126-x. Epub 2012 Nov 24. Clin Rheumatol. 2013. PMID: 23179008
-
Calcitonin, estradiol, and hydroxyproline as parameters in the early diagnosis of involutional osteoporosis. The importance of the "second calcitonin phenomenon".Arch Orthop Trauma Surg. 1990;109(4):181-5. doi: 10.1007/BF00453137. Arch Orthop Trauma Surg. 1990. PMID: 2383444
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical